TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04409509

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody
Description: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody administered intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: CSL312 diluent administered intravenously
Study: NCT01345227

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra bone marrow islet infusion
Description: A needle for bone marrow aspiration (14 G) will be inserted into the superior-posterior iliac crest and islet suspension (1:2.5; tissue:Ringer's Lactate solution) will be infused. The entire intraBM-injection procedure last 8-15 min from the beginning of anaesthesia (short propofol sedation).
Study: NCT01225601

Intervention type: BEHAVIORAL
Intervention: Tabacco discontinuation
Description: Tabacco discontinuation
Study: NCT04299126

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high absorption pad for blood and pus
Description: High absorption pad for blood and pus will be covered on half of split-thickness skin graft donor site wound until the wound has healed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: commercial wound dressing
Description: Commercial wound dressing will be covered on half of split-thickness skin graft donor site wound until the wound has healed.
Study: NCT02454621

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Volitional help sheet
Description: Participants are asked to form implementation intentions using a volitional help sheet (Armitage, 2008).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volitional help sheet
Description: Participants are asked to form implementation intentions using a volitional help sheet (Armitage, 2008).
Study: NCT02822027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human gamma globulin
Description: human gamma globulin for preterm infants with encephalopathy of prematurities

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human gamma globulin
Description: human gamma globulin for preterm infants with encephalopathy of prematurities

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: non-human gamma globulin
Description: Non-human gamma globulin for preterm infants with encephalopathy of prematurities

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: non-human gamma globulin
Description: Non-human gamma globulin for preterm infants with encephalopathy of prematurities
Study: NCT02233673

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentives
Description: Participants receive a behavioral intervention and financial incentives for meeting gestational weight gain goals.
Study: NCT03066466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Oral medication given to prevent graft versus host disease in bone marrow transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: IV medication given to prevent graft versus host disease in bone marrow transplant.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: IV medication given to prevent graft versus host disease in bone marrow transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: IV or Oral medication given to prevent graft versus host disease in bone marrow transplant.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: IV or Oral medication given to prevent graft versus host disease in bone marrow transplant.
Study: NCT02304770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminolaevulinic acid photodynamic therapy
Description: Aminolaevulinic acid mediated photodynamic therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminolaevulinic acid photodynamic therapy
Description: Aminolaevulinic acid mediated photodynamic therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminolaevulinic acid photodynamic therapy
Description: Aminolaevulinic acid mediated photodynamic therapy
Study: NCT02334046

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 1.8 ng/ml) in elderly patients (65-80 years) .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 1.8 ng/ml) in adult patients (20-60 years) .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Anesthesia was maintained with sevoflurane with 1.5-2.0 vol% in air/50%oxygen mixture, and sevoflurane was adjusted to about 1.0 vol% 10 min before end of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Anesthesia was maintained with sevoflurane with 1.5-2.0 vol% in air/50%oxygen mixture, and sevoflurane was adjusted to about 1.0 vol% 10 min before end of surgery.
Study: NCT03562676

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: weightlessness
Description: parabolic flight
Study: NCT00716365

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HemCon bandage
Description: 5 cm X 5 cm
Study: NCT00451191

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin type A (BoNT/A)
Description: 100 unit and 300 unit dosages: Dilute each 100 U vial with 1.3 ml of normal saline. Each reconstituted vial is then drawn up into a single syringe with a total of 4 ml = 300 U. The instrument used to inject the botulinum toxin is an ultrasound device with a transrectal ultrasound probe specially designed for prostate biopsies which has a special canal to introduce and direct a needle in to the selected prostatic area.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin type A (BoNT/A)
Description: 100 unit and 300 unit dosages: Dilute each 100 U vial with 1.3 ml of normal saline. Each reconstituted vial is then drawn up into a single syringe with a total of 4 ml = 300 U. The instrument used to inject the botulinum toxin is an ultrasound device with a transrectal ultrasound probe specially designed for prostate biopsies which has a special canal to introduce and direct a needle in to the selected prostatic area.
Study: NCT01605370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: Nebivolol 2.5 mg once daily

Intervention type: DRUG
Group type: OTHER
Intervention: Metoprolol succinate
Description: Metoprolol succinate 50 mg once daily
Study: NCT01929551

Intervention type: OTHER
Group type: OTHER
Intervention: Mango puree and pear juice beverage
Description: Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.

Intervention type: OTHER
Group type: OTHER
Intervention: Commercial mango juice
Description: Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.

Intervention type: OTHER
Group type: OTHER
Intervention: Fresh natural mango
Description: Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.

Intervention type: OTHER
Group type: OTHER
Intervention: Frozen natural mango
Description: Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.

Intervention type: OTHER
Group type: OTHER
Intervention: Processed natural mango pulp
Description: Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.

Intervention type: OTHER
Group type: OTHER
Intervention: Mix of natural mango and pear
Description: Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.

Intervention type: OTHER
Group type: OTHER
Intervention: 50 grams glucose load
Description: Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
Study: NCT00227591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03455842

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-089, 162 mg, s/c, qw
Description: Subcutaneous injections of anti-IL6R every week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-089, 162 mg, s/c, q2w
Description: Subcutaneous injections of anti-IL6R every other week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subcutaneous injections of placebo every week, until week 12. Thereafter subcutaneous injections of anti-IL6R every other week
Study: NCT02341482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Administered as specified in the treatment arm
Study: NCT04980196

Intervention type: DIAGNOSTIC_TEST
Intervention: urodynaemic studies
Description: The Urodynamic studies carried out were : uroflowmetry and cystometry. The Uroflowmetry was performed by the gravimetric method Detrusor over activity was diagnosed when the patient has involuntary detrusor contractions during filling with or without leakage which may be spontaneous or provoked,
Study: NCT03986216

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReIn-Hand device assisted home-based practice
Description: Practice reach-grasp-retrieve-release at home with the aid of ReIn-hand device
Study: NCT01886105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sm-EDTMP
Description: Subjects receive a tracer infusion of Samarium-153 EDTMP at 1 mCi/kg. 3D dosimetry using SPECT images are obtained post tracer infusion to determine the distribution of dose delivered to the tumor and surrounding normal tissues. Tracer activity will be applied to development of the external beam radiation (EBT) planning. Second treatment infusion of Samarium will then be implemented. Maximum activity administered will be 30 mCi/kg.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Infusion
Description: Administered 14 days after Treatment infusion of Samarium-153 EDTMP.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiotherapy
Description: The radiotherapy portion of the combined plan will be delivered according to the judgement of the treating radiation oncologist. The total dose to be used will be modified based on surrounding tissue tolerances as evidenced by Samarium infusion and SPECT image planning.~After the treatment infusion, SPECT scans will again be performed to confirm the total dose delivered and subsequently adjust the EBT portion of the treatment plan, as necessary.
Study: NCT03445325

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LiGHT v2.1
Description: The LiGHT mobile program strives to support youth and their families to adopt lifelong healthy behaviours in four areas - eating, physical activity, recreational screen time and sleep - to foster healthy growth and development, to prevent chronic diseases and manage unhealthy weights.~The program includes content that involve the family, and focus on behavioural therapy as well as dietary and physical activity patterns. LiGHT is intended to be engaging and fun, provide virtual and tangible rewards, and interact with participants multiple times per day. In addition, it will feature a mobile social support network and interaction with a live coach with specialized training in motivational interviewing to support youth/families in changing their health behaviours through messaging and phone calls.
Study: NCT02032433

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended-Release Naltrexone
Description: Extended-Release Naltrexone (Vivitrol®)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine-Naloxone
Description: Buprenorphine-Naloxone (Suboxone®)
Study: NCT00493701

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: High Fat Diet
Description: Daily eating

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Low Fat Diet
Description: Life style eating habits
Study: NCT02205281

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: The intervention is a multi-component program designed to prevent excessive gestational weight gain in overweight and obese women and to promote weight loss in their non-pregnant overweight and obese partners through modifications of diet, exercise, and behavioral strategies during pregnancy.
Study: NCT01454037

Intervention type: PROCEDURE
Intervention: Prostate cryotherapy
Description: cryoablate the prostate

Intervention type: PROCEDURE
Intervention: Radical prostatectomy
Description: Remove prostate

Intervention type: PROCEDURE
Intervention: Radiation
Description: Radiate prostate
Study: NCT04120116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX-322 (One Dose)
Description: Patients will receive one dose of FX-322.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX-322 (Two Doses)
Description: Patients will receive two doses of FX-322.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX-322 (Four Doses)
Description: Patients will receive four doses of FX-322.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients will receive Placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients will receive Placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive Placebo.
Study: NCT03410693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rogaratinib (BAY1163877)
Description: Rogaratinib administered as oral (p.o.) tablets twice daily (b.i.d.) continuously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Chemotherapy as taxane (docetaxel or paclitaxel) or vinflunine administered through intravenous (i.v.) infusion every 3 weeks (on day 1 of a 21-day cycle) The choice of the chemotherapy is at the discretion of the investigator, taking into consideration the status of the authorization or treatment guidelines in the given country.
Study: NCT04188613

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous tracheostomy
Description: Age, gender, height, BMI, ASA scores, presence and type of additional diseases, tracheostomy day, pre- and post-procedure blood gas analysis, duration of procedure, duration of anesthesia, complications during the procedure (bleeding , desaturation, accidental extubation, malposition, bradycardia, hypotension, etc.) will be recorded from intensive care follow-up. Patients will be observed for mortality in the first 30 days after the procedure. Mortality results will be recorded.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous tracheostomy
Description: Age, gender, height, BMI, ASA scores, presence and type of additional diseases, tracheostomy day, pre- and post-procedure blood gas analysis, duration of procedure, duration of anesthesia, complications during the procedure (bleeding , desaturation, accidental extubation, malposition, bradycardia, hypotension, etc.) will be recorded from intensive care follow-up. Patients will be observed for mortality in the first 30 days after the procedure. Mortality results will be recorded.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous tracheostomy
Description: Age, gender, height, BMI, ASA scores, presence and type of additional diseases, tracheostomy day, pre- and post-procedure blood gas analysis, duration of procedure, duration of anesthesia, complications during the procedure (bleeding , desaturation, accidental extubation, malposition, bradycardia, hypotension, etc.) will be recorded from intensive care follow-up. Patients will be observed for mortality in the first 30 days after the procedure. Mortality results will be recorded.
Study: NCT02267018

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drager VN500 Ventilator
Description: This ventilator is capable of providing both nCPAP and NIHFV support.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drager VN500 Ventilator
Description: This ventilator is capable of providing both nCPAP and NIHFV support.
Study: NCT05252299

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rolling Fresher Group
Description: The use of telemedicine to provide remote CSS installation instruction via audio and visual input by a Certified child passenger safety technician (CPST)
Study: NCT03373188

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Undergo therapeutic conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Undergo therapeutic conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Undergo therapeutic conventional surgery
Study: NCT02406911

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: After randomization, each group will be treated as assigned dose of ticagrelor (ticagrelor 90mg once a day or 90mg twice a day) for 14 days. After 1 week wash-out period, cross-over study will be performed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: After randomization, each group will be treated as assigned dose of ticagrelor (ticagrelor 90mg once a day or 90mg twice a day) for 14 days. After 1 week wash-out period, cross-over study will be performed
Study: NCT04709445

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ICG-NIRF Imaging plus ingress and egress analysis
Description: intraoperative NIRF Imaging using the fluorescence agent ICG (indocyanine-green) before and after anastomosis formation, postoperative analysis of ingress and egress for specific regions of interest
Study: NCT00532688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: 28 days of oral n-acetylcysteine (500mg bd)(in addition to standard therapy) and then repeat serum creatinine and vascular study then crossover to placebo for 28 days after one week washout period with tests repeated again at 4 weeks and 9 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: N-acetylcysteine
Description: 28 days of oral n-acetylcysteine (500mg bd)(in addition to standard therapy) and then repeat serum creatinine and vascular study then crossover to placebo for 28 days after one week washout period with tests repeated again at 4 weeks and 9 weeks.
Study: NCT01285934

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: All participants randomized to the transplant arm wil undergo Autologous Hematopoietic Stem Cell Transplantation

Intervention type: DRUG
Group type: OTHER
Intervention: intensive insulin therapy
Description: The control arm will be either CSII via an insulin pump or intensive subcutaneous insulin therapy with multiple insulin injections (at least 4/day) utilizing a long acting background insulin and pre-meal rapid acting insulin.
Study: NCT03828331

Intervention type: OTHER
Intervention: Prosthetic/Bicycle Configuration
Description: The investigators will measure the biomechanics (motion, forces, and muscle activity) and metabolic rates while subjects ride using an initial bike fit and three taller pylon lengths (PL) for the affected leg (AL) in increments of 6.8 mm using a pedal attachment position (PAP) beneath the prosthetic forefoot. Then, using the optimal (most efficient) PL, the investigators will measure the biomechanics and metabolic rates while subjects ride using three shorter crank arm lengths (CALs) for the AL in decrements of 6.8 mm using a PAP beneath the prosthetic forefoot. On Day 2, the investigators will repeat the protocol of Day 1, but have riders use a PAP beneath the pylon for their AL.
Study: NCT04042324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triferic
Description: Triferic (ferric pyrophosphate citrate, FPC), an iron-replacement product, is an iron complex in which iron(III) is bound to pyrophosphate and citrate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triferic
Description: Triferic (ferric pyrophosphate citrate, FPC), an iron-replacement product, is an iron complex in which iron(III) is bound to pyrophosphate and citrate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Unfractionated heparin (UFH): a common anticoagulant used during hemodialysis treatments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Unfractionated heparin (UFH): a common anticoagulant used during hemodialysis treatments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Unfractionated heparin (UFH): a common anticoagulant used during hemodialysis treatments.